These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27666584)

  • 1. Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Emmanuel B; Sidique N; Zhang X; Poonia B; Sneller MC; Kottilil S
    J Viral Hepat; 2017 Feb; 24(2):128-131. PubMed ID: 27666584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of hepatitis C specific T-cell responses after rituximab therapy in hepatitis C mixed cryoglobulinemic vasculitis.
    Mathur P; Emmanuel B; Sneller M; Zhang X; Poonia B; Kottilil S
    J Med Virol; 2018 May; 90(5):936-941. PubMed ID: 29236302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis.
    Saadoun D; Delluc A; Piette JC; Cacoub P
    Curr Opin Rheumatol; 2008 Jan; 20(1):23-8. PubMed ID: 18281853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.
    Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P
    Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
    Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
    Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and risk of rituximab in type II mixed cryoglobulinemia: a significant case report.
    Massari M; Catania A; Magnani G
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S134-5. PubMed ID: 17936216
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
    Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
    Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dilemma of treating hepatitis C virus-associated cryoglobulinemia.
    Roccatello D; Fenoglio R; Sciascia S
    Curr Opin Rheumatol; 2019 Sep; 31(5):499-504. PubMed ID: 31090590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.
    Saadoun D; Resche-Rigon M; Sene D; Perard L; Karras A; Cacoub P
    Ann Rheum Dis; 2008 Oct; 67(10):1431-6. PubMed ID: 18178690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.
    Sneller MC; Hu Z; Langford CA
    Arthritis Rheum; 2012 Mar; 64(3):835-42. PubMed ID: 22147444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: A pilot study.
    Saadoun D; Ghembaza A; Riviere S; Mekinian A; Boutemy J; Leroux G; Domont F; Maillard H; Vautier M; Cacoub P
    J Autoimmun; 2021 Jan; 116():102577. PubMed ID: 33248866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C virus-related cryoglobulinemic vasculitis.
    Mazzaro C; Mauro E; Ermacora A; Doretto P; Fumagalli S; Tonizzo M; Toffolutti F; Gattei V
    Minerva Med; 2021 Apr; 112(2):175-187. PubMed ID: 33198444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature.
    Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S
    Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of long-term treatment with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis.
    Colantuono S; Mitrevski M; Yang B; Tola J; Carlesimo M; De Sanctis GM; Fiorilli M; Casato M; Visentini M
    Clin Rheumatol; 2017 Mar; 36(3):617-623. PubMed ID: 28111716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab.
    Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell depletion in the treatment of mixed cryoglobulinemia.
    Sansonno D; Tucci FA; Montrone M; Troiani L; Sansonno L; Gatti P; Lauletta G
    Dig Liver Dis; 2007 Sep; 39 Suppl 1():S116-21. PubMed ID: 17936212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life in severe cryoglobulinaemic vasculitis and improvement after B-cell depleting therapy.
    Quartuccio L; Isola M; Masolini P; Scaini P; Zani R; Tavoni A; Pietrogrande M; Bombardieri S; De Vita S
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S9-14. PubMed ID: 23044040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents.
    Roccatello D; Sciascia S; Rossi D; Solfietti L; Fenoglio R; Menegatti E; Baldovino S
    Oncotarget; 2017 Jun; 8(25):41764-41777. PubMed ID: 28454112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study.
    Quartuccio L; Zuliani F; Corazza L; Scaini P; Zani R; Lenzi M; Tavoni A; Sebastiani M; Baldovino S; Urraro T; Saccardo F; Sbreglia C; Mazzaro C; Pioltelli P; Fraticelli P; Filippini D; Gabrielli A; Perrella O; Scarpato S; Roccatello D; Zignego AL; Ferri C; Bombardieri S; Pietrogrande M; Monti G; Galli M; De Vita S
    J Autoimmun; 2015 Sep; 63():88-93. PubMed ID: 26255249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.